Search the NeLM

Medicines A-Z
Find key information about medicines by name (prototype)
NeLM news service
Review: Anaemia and renal dysfunction in chronic heart failure

Reference: Heart 2009;95:1808-1812

Source: Heart

Date published: 27/10/2009 15:47

Summary
by: Hina Radia

Heart has featured a review discussing the aetiology, consequences and treatment of anaemic patients with heart failure and renal dysfunction.

 

The following is considered:
• How common is the combination of anaemia and heart failure?
• What causes anaemia in heart failure patients?
• How to treat anaemia in chronic HF and renal dysfunction
• Are there potential side effects of erythropoietin (EPO) treatment?
• Non-erythropoietic effects of EPO

Extract

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.
Related evidence
2.5.5 Drugs affecting the renin-angiotensin system
11/10/2011
Scottish Medicines Consortium accepts Sevikar HCT® (olmesartan medoxomil, amlodipine besilate and hydrochlorothiazide) for use in NHS Scotland
11/10/2011
Scottish Medicines Consortium accepts Sevikar HCT® (olmesartan medoxomil, amlodipine besilate and hydrochlorothiazide) for use in NHS Scotland
11/10/2011
Scottish Medicines Consortium accepts Sevikar HCT® (olmesartan medoxomil, amlodipine besilate and hydrochlorothiazide) for use in NHS Scotland
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias
05/04/2011
Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia: summary of trials of cancer, HIV/AIDS, and chronic kidney disease
09/02/2011
NICE issues clinical guideline on the management of anaemia in people with chronic kidney disease
22/11/2010
AWMSG recommends epoetin theta (Eporatio®) for restricted use within NHS Wales
Anaemias
06/09/2011
AWMSG issues Final Appraisal Recommendation on ferric carboxymaltose (Ferinject®)
09/05/2011
SMC accepts restricted use of iron isomaltoside (Monofer) within NHS Scotland.
05/04/2011
Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia: summary of trials of cancer, HIV/AIDS, and chronic kidney disease
Heart Failure
03/02/2011
Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials
25/08/2010
NICE issues clinical guidance on the management of chronic heart failure in adults in primary and secondary care
30/06/2009
CKS Topic review: Chronic heart failure
Renal medicine
05/02/2012
Parenteral versus oral iron therapy for adults and children with chronic kidney disease
08/08/2011
SMC accepts restricted use of alteplase (Actilyse Cathflo®) for thrombolytic treatment of occluded central venous access devices
27/07/2011
NICE issues clinical guideline on peritoneal dialysis in the treatment of stage 5 chronic kidney disease (CG 125)
Related news
2.5.5 Drugs affecting the renin-angiotensin system
12/01/2012
Case control study: Antihypertensive drugs and risk of incident gout among patients with hypertension
10/01/2012
Meta-analysis: The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury
04/01/2012
Direct Healthcare Professional Communication on potential risks of cardiovascular and renal adverse events with aliskiren (Rasilez™)
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias
01/02/2012
Stock shortages of Xenical® 120mg caps and Mircera® Pre-filled Syringe
26/01/2012
Review: Diagnosis and management of thalassaemia
26/01/2012
Review: Mechanisms of disease- iron overload
Anaemias
13/12/2011
Health Canada approves ferumoxytol (Feraheme®) for the treatment of iron deficiency in adults with CKD
08/12/2011
FDA advisory panel supports approval of peginesatide for treatment of anaemia in dialysis patients in US
25/10/2011
Horizon scanning: US FDA accepts for review peginesatide for the treatment of anaemia associated with chronic kidney disease
Heart Failure
09/02/2012
National Heart Failure Audit annual report 2010/11
01/02/2012
National Heart Failure audit 2010-11
16/12/2011
European CHMP recommends approval of license extension for ivabradine (Procoralan) as treatment of chronic heart failure (NYHA II to IV) and updates contra-indications
Renal medicine
07/02/2012
Systematic Review: Estimating equations for GFR in the era of creatinine standardisation
02/02/2012
Baxter Communication: Resumption of distribution of Monosol solution
26/01/2012
FDA approves updated label but not new indication for Vytorin®(ezetimibe/simvastatin) to incorporate data from SHARP
Back